Figure 2.
BILAG-based Combined Lupus Assessment response rate (A) at week 12 (intention-to-treat analysis) for all patient groups (B) over weeks 1–12 for the 2400 mg combined dose arms compared with the placebo group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.